Developing peptide therapeutics presents distinct challenges from managing impurity profiles across complex sequences to navigating the scale-up risks as programs move from clinical to commercial manufacturing, all while meeting stringent global regulatory requirements.
With over four decades of complex API development experience, Neuland Labs enables custom peptide synthesis services spanning milligram to multi-kilogram scale — bringing the process expertise, analytical rigour, and cGMP infrastructure to address these challenges at every stage.
Peptide Synthesis Capabilities
Neuland supports a broad range of peptide services through three core synthesis approaches, each selected based on peptide length, complexity, and production scale. Here is an overview of our peptide synthesis technologies
Peptide Modalities Supported
- Linear & long‑chain peptides
- Cyclic & disulfide‑bridged peptides
- PEGylated / lipidated peptides
- Azido peptides and Click‑chemistry–enabled peptides
- Peptide fragments & building blocks
Process Development & Scale-Up Strategy
Neuland's approach to peptide process development is built around establishing critical process parameters (CPP) and critical quality attributes (CQA) early. Our scientists lead synthetic route scouting to design shorter, more efficient routes for large-scale peptide synthesis, particularly where existing methods are impractical for scale-up. This draws on combined expertise across synthetic, medicinal, and preparative chemistry.
Beyond route design, our peptide API development services include detailed impurity profiling at trace, alongside forced degradation studies and stability assessments that define shelf life and storage conditions.
Explore Process Development Capabilities
Large Scale cGMP Peptide Manufacturing
Neuland operates under global cGMP peptide manufacturing standards — USFDA, EMA, and PMDA — with 21 CFR Part 11–compliant data integrity systems, DCS-based automation with eBMR integration, and segregated suites to ensure product quality and regulatory readiness.
Our newest facility is expected to be commercially operational by summer 2026, delivering 6,370 litres of combined SPPS and LPPS reactor capacity in its first module.
This complements Neuland's existing 1,174,000 litres of API manufacturing capacity across three USFDA-approved facilities.
View cGMP Manufacturing CapabilitiesAnalytical Development and Validation
Reliable analytical methods are the backbone of successful peptide API development. Neuland's analytical R&D team supports every stage of your peptide program with method development, validation, and ongoing quality control.
Our analytical capabilities include method validation and transfer, impurity profiling and characterisation, stability studies under ICH guidelines, and analytical reference standard development. The team works across advanced instrumentation including UPLC, HPLC, GC-MS, QTOF-HRMS, circular dichroism, and fluorescence spectroscopy.
See Our Analytical Approach
Built for Program Continuity
When your peptide program stays with a single development and manufacturing partner, the advantages compound at every stage. Working with Neuland means:
- No disruptive vendor transitions or technology transfers between phases
- Validated parameters carry forward from early development through commercial-scale production
- Our CMC and regulatory teams bring prior experience with global regulatory interactions, reducing documentation risk and accelerating filing readiness
- The scientists who develop your process are embedded through scale-up and manufacturing, preserving critical institutional understanding of your molecule
Why Choose Neuland for Peptide Manufacturing
From process development and route scouting through cGMP manufacturing and analytical validation, Neuland manages the full peptide development lifecycle under one roof, eliminating handoff delays and reducing project risk.
With a new commercial peptide facility coming in 2026 and a modular design that supports phased expansion, Neuland offers the flexibility to scale with your program, from early clinical batches to multi-ton commercial supply.
Neuland brings over 4 decades of complex API development experience to peptide programs, with proven capabilities in SPPS, LPPS, hybrid synthesis, and advanced purification, including cyclic peptides, PEGylated peptides, and click chemistry.
All facilities operate under global cGMP standards with USFDA, EMA, and PMDA compliance, supported by robust QA/QC systems, 21 CFR Part 11–compliant data integrity, and a strong track record of regulatory filings on behalf of customers.
As a root source of over 150 FMOC building blocks for global peptide vendors and innovator companies, Neuland strengthens upstream supply chain security, reducing dependency on third-party suppliers for critical raw materials.
FAQ's
A peptide CDMO, or Contract Development and Manufacturing Organisation, is a specialised partner that handles the development and manufacturing of peptide-based active pharmaceutical ingredients on behalf of pharmaceutical and biotech companies. As a dedicated peptide CDMO, Neuland provides expertise in custom peptide synthesis services, including process development, analytical validation, and cGMP manufacturing, enabling drug developers to advance peptide programs from early development through commercial supply without building in‑house infrastructure.
Neuland manufactures peptides across a range of lengths using multiple synthesis approaches. Most peptides between five and sixty amino acids are produced by solid phase peptide synthesis (SPPS). Shorter peptides of up to ten amino acids are manufactured via solution phase synthesis for multi-kilogram quantities. For longer or more complex peptides containing up to forty amino acids, segment condensation and ligation techniques are employed.
Yes, Neuland offers cGMP peptide manufacturing at both clinical and commercial scale. Our facilities operate under global cGMP standards, including compliance with USFDA, EMA, and PMDA requirements, with segregated suites and 21 CFR Part 11–compliant data integrity systems to ensure product quality, audit readiness, and regulatory acceptance for clinical and commercial peptide APIs.
Neuland supports peptide programs from early-stage process development through to commercial-scale production. Our newest facility at Bonthapally provides 6,370 litres of combined SPPS and LPPS reactor capacity, with a modular design that supports expansion as programs scale. This infrastructure enables seamless progression from small clinical batches to multi‑ton commercial volumes under a single quality system, without the need for route re‑optimisation.
Yes, Neuland supports clinical trial peptide manufacturing across all phases. Our phase-appropriate development approach ensures that synthesis, purification, and quality control processes are optimised for each stage of your clinical program — from preclinical development through to Phase III while maintaining continuity toward eventual commercial manufacturing.
Neuland has demonstrated expertise in complex and modified peptide synthesis. This includes cyclic peptides with multiple disulfide bonds, PEGylated peptides, azido-peptides for click chemistry, and peptides requiring segment condensation or ligation techniques. Our hybrid technology platform combines solid and liquid phase methods to address structural complexity while maintaining purity and scalability.
Neuland provides comprehensive analytical development and regulatory support for peptide programs. Custom peptide synthesis services include method development and validation, impurity profiling, stability studies, and characterisation using advanced instrumentation. Our regulatory CMC support team assists with documentation and filings to facilitate smooth regulatory submissions and approval-ready peptide APIs.
